Tearsheet
MAZE Home Investment Highlights Valuation, Metrics & Events Price Chart Why The Stock Moved Return vs. Risk About MAZE Interactive Breakdown Better Bets vs. MAZE Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Trade Sentinel Industry Resource Links External Quote Links

Maze Therapeutics (MAZE)

Market Price (2/20/2026): $44.5 | Market Cap: $2.0 Bil
Sector: Health Care | Industry: Biotechnology

Maze Therapeutics (MAZE)

Market Price (2/20/2026): $44.5
Market Cap: $2.0 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -17%		 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
1 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Genetics-based Drug Discovery, Targeted Therapies, Show more.		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -135 Mil
2  Stock price has recently run up significantly
6M Rtn6 month market price return is 240%, 12M Rtn12 month market price return is 259%
3  Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg QQuarterly Revenue Change % is null
4  Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10%
5  Key risks
MAZE key risks include [1] its heavy dependence on the clinical and commercial success of its limited lead candidates, Show more.
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -17%
1 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Genetics-based Drug Discovery, Targeted Therapies, Show more.
2 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -135 Mil
4 Stock price has recently run up significantly
6M Rtn6 month market price return is 240%, 12M Rtn12 month market price return is 259%
5 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg QQuarterly Revenue Change % is null
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10%
7 Key risks
MAZE key risks include [1] its heavy dependence on the clinical and commercial success of its limited lead candidates, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Maze Therapeutics (MAZE) stock has gained about 35% since 10/31/2025 because of the following key factors:

1. Continued advancement and positive outlook for key clinical programs.

Maze Therapeutics provided positive updates on its lead drug candidates, MZE829 and MZE782, which significantly contributed to investor confidence. In November 2025, the company reported third-quarter financial results and highlighted the advancement of both MZE829 and MZE782 programs, with additional data presented at ASN Kidney Week. MZE829 is progressing in Phase 2 trials for APOL1 kidney disease, with initial data anticipated in the first quarter of 2026, creating positive anticipation among investors. Furthermore, positive Phase 1 healthy volunteer data for MZE782, a treatment for phenylketonuria (PKU) and chronic kidney disease (CKD), was announced in September 2025, establishing proof of mechanism and setting the stage for Phase 2 trials to begin, a critical step that continued to bolster the stock's upward trajectory within the period.

2. Increasingly bullish analyst ratings and significant price target increases.

Analysts demonstrated growing optimism for Maze Therapeutics, with a consensus "Buy" rating and notable increases in price targets during this period. As of October 31, 2025, analysts already held an optimistic outlook with several "buy" ratings. This sentiment strengthened significantly into early 2026, with a January 20, 2026, report highlighting largely bullish analyst sentiment, a consensus "Buy" rating, and an average price target of $44.50. Notably, firms like HC Wainwright raised their price objectives as high as $60.00 in December 2025, reflecting strong conviction in the company's future prospects. By February 6, 2026, the analyst sentiment remained overwhelmingly positive, with 10 buy ratings and an average target price of $49.44, indicating further upside potential.

Show more

Stock Movement Drivers

Fundamental Drivers

The 36.9% change in MAZE stock from 10/31/2025 to 2/19/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.
(LTM values as of)103120252192026Change
Stock Price ($)32.9145.0436.9%
Change Contribution By: 
Total Revenues ($ Mil)20 
P/S Multiple576.5∞9.2233720368547763E17%
Shares Outstanding (Mil)4446-4.3%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 2/19/2026
ReturnCorrelation
MAZE36.9% 
Market (SPY)0.4%17.9%
Sector (XLV)9.0%6.7%

Fundamental Drivers

The 205.4% change in MAZE stock from 7/31/2025 to 2/19/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)73120252192026Change
Stock Price ($)14.7545.04205.4%
Change Contribution By: 
Total Revenues ($ Mil)�00.0%
P/S Multiple�∞0.0%
Shares Outstanding (Mil)3546-23.6%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2025 to 2/19/2026
ReturnCorrelation
MAZE205.4% 
Market (SPY)8.6%17.5%
Sector (XLV)21.1%22.6%

Fundamental Drivers

The 182.4% change in MAZE stock from 1/31/2025 to 2/19/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)13120252192026Change
Stock Price ($)15.9545.04182.4%
Change Contribution By: 
Total Revenues ($ Mil)�00.0%
P/S Multiple�∞0.0%
Shares Outstanding (Mil)3546-23.6%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2025 to 2/19/2026
ReturnCorrelation
MAZE182.4% 
Market (SPY)14.7%17.8%
Sector (XLV)8.5%19.7%

Fundamental Drivers

null
null

Market Drivers

1/31/2023 to 2/19/2026
ReturnCorrelation
MAZE  
Market (SPY)74.7%17.8%
Sector (XLV)23.4%19.7%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
MAZE Return----160%9%183%
Peers Return-26%-13%-15%-50%-32%4%-81%
S&P 500 Return27%-19%24%23%16%1%83%

Monthly Win Rates [3]
MAZE Win Rate----58%100% 
Peers Win Rate33%58%54%38%56%50% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
MAZE Max Drawdown-----53%-7% 
Peers Max Drawdown-37%-32%-42%-51%-49%-7% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-1% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, AKTS, ALPS, DCOY, DFTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/19/2026 (YTD)

How Low Can It Go

MAZE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique KeyEventXLVS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-16.1%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven19.1%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven599 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-28.8%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven40.4%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven116 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-15.8%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven18.8%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven326 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-40.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven68.3%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1,100 days1,480 days

Compare to VRTX, AKTS, ALPS, DCOY, DFTX

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Maze Therapeutics (MAZE)

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

AI Analysis | Feedback

1. An early-stage Vertex Pharmaceuticals, but using a genetic platform to discover precision small molecule drugs for a broader range of genetic diseases.

2. Like Moderna, but applying a genetic insights platform to discover small molecule drugs for a wide range of genetic diseases, rather than mRNA therapeutics.

AI Analysis | Feedback

  • MZE001: An investigational oral therapy in clinical development for the treatment of Pompe disease, a rare genetic disorder.
  • Early-Stage Precision Medicine Candidates: Preclinical drug candidates being developed through their human genetics platform for various other rare genetic diseases.

AI Analysis | Feedback

As a clinical-stage biotechnology company, Maze Therapeutics (MAZE) is primarily engaged in the research and development of precision medicines for common diseases with a genetic basis. The company does not currently have any commercial products on the market.

Based on its latest financial reports, including the Form 10-Q for the quarter ended March 31, 2024, Maze Therapeutics reported no revenue from product sales or collaborations. This indicates that the company does not currently have any commercial products on the market generating sales.

Therefore, Maze Therapeutics does not currently have major customers in the traditional sense of selling products or services to other companies or individuals. Its operations are funded through equity financing and other investments to advance its drug pipeline through clinical trials.

AI Analysis | Feedback

null

AI Analysis | Feedback

Jason Coloma, Chief Executive Officer, President, Director

Dr. Jason Coloma was appointed CEO of Maze Therapeutics in July 2019. He was instrumental in founding and launching the company, having served as a venture partner at Third Rock Ventures, a venture capital firm, prior to his CEO appointment. While at Third Rock, he focused on new company creation and held interim Chief Business Officer roles at insitro and Celsius Therapeutics. Dr. Coloma also served as interim Chief Operating Officer of Maze Therapeutics. His previous experience includes serving as Senior Vice President and Chief Business Officer at Corvus Pharmaceuticals and various leadership roles at Roche, including Vice President & Global Therapeutic Area Head of Oncology and Cancer Immunotherapy Partnering. He also worked in finance at Amgen and in research at the University of California, San Francisco and Cytokinetics, and was a consultant at L.E.K. Consulting.

Misbah Tahir, Chief Financial Officer

Misbah Tahir was appointed Chief Financial Officer of Maze Therapeutics in September 2025, bringing over two decades of financial and strategic leadership experience in the biopharmaceutical industry. Before joining Maze, he served as CFO at IGM Biosciences, Inc., where he played a key role in guiding the company through its 2019 initial public offering and helped raise over $1 billion through various equity financings and a pharmaceutical partnership. Mr. Tahir held senior finance positions at Dermira, Inc. (acquired by Eli Lilly and Company), Onyx Pharmaceuticals, Inc. (acquired by Amgen Inc.), and Human Genome Sciences Inc. (acquired by GSK plc), where he contributed significantly to capital formation, strategic partnerships, and product launches. He began his career in the biopharmaceutical sector at Amgen, Inc. after working as a management consultant with Oliver Wyman.

Atul Dandekar, Chief Strategy Officer

Atul Dandekar serves as the Chief Strategy Officer at Maze Therapeutics.

David Morgans, Executive Vice President, Drug Discovery

David Morgans is the Executive Vice President of Drug Discovery at Maze Therapeutics.

Matthew Krause, Senior Vice President, Human Resources

Matthew Krause holds the position of Senior Vice President, Human Resources at Maze Therapeutics.

AI Analysis | Feedback

The key risks to Maze Therapeutics (MAZE) business are primarily associated with the high-risk nature of a clinical-stage biopharmaceutical company focused on developing novel precision medicines.

  1. Dependence on Lead Programs and Clinical Trial Success: Maze Therapeutics' future success is highly contingent on the successful clinical development, regulatory approval, and commercialization of its limited number of lead therapeutic candidates, specifically MZE829, MZE782, and MZE001. Any setbacks in clinical trials, such as safety concerns, efficacy issues, or delays, could significantly impact the company's prospects and amplify its risk profile.
  2. Lack of Profitability and Significant Cash Burn: As a clinical-stage company, Maze Therapeutics currently operates without product revenue and incurs substantial operating losses. The company reports negative earnings per share, negative return on equity, and negative free cash flow due to heavy investment in research and development. While recent funding has provided a cash runway of approximately 3.6 years as of September 2025, sustained profitability is contingent upon the successful development and market acceptance of its therapeutic candidates, making its financial health a significant long-term risk.
  3. Regulatory Hurdles and Market Access Challenges: Bringing new therapeutic candidates to market requires navigating complex and stringent regulatory pathways. Maze Therapeutics faces the significant challenge of obtaining regulatory approvals for its drug candidates. Failure to secure these approvals or difficulties in achieving favorable market access and reimbursement could severely hinder the company's ability to commercialize its products and generate revenue.

AI Analysis | Feedback

Clear emerging threats to Maze Therapeutics (MAZE) include:

  • Competition in APOL1-mediated kidney disease: Vertex Pharmaceuticals has a drug candidate, VX-1473, which is in Phase 3 clinical trials for APOL1-mediated kidney disease. This is significantly ahead of Maze's preclinical MAZE-800 program targeting the same indication. The potential approval and market entry of VX-1473 could capture a substantial portion of the patient population before Maze's candidate even enters clinical development, severely limiting its future market opportunity.

  • Competition in TREM2-mediated neurodegenerative diseases (e.g., ALS/FTD): Vigil Neuroscience is developing VGL101, a TREM2-activating antibody, which is in Phase 2 clinical trials for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and has completed Phase 1 for Alzheimer's disease. This program is significantly ahead of Maze's preclinical TREM2 program for ALS/FTD. Successful development and potential approval of VGL101 could establish Vigil Neuroscience as a leader in TREM2 modulation, potentially diminishing the market opportunity for Maze's later-stage candidate.

AI Analysis | Feedback

The addressable markets for Maze Therapeutics' main products are as follows:

  • MZE829 (APOL1-mediated kidney disease - AMKD): The addressable market for AMKD is estimated to affect over one million people in the United States alone.
  • MZE782 (Chronic Kidney Disease - CKD): For chronic kidney disease, MZE782 has the potential to treat approximately five million U.S. patients who inadequately respond to currently available therapies.
  • MZE782 (Phenylketonuria - PKU): While MZE782 is also being developed for Phenylketonuria (PKU), a specific addressable market size for PKU was not provided in the search results.

AI Analysis | Feedback

Maze Therapeutics (NASDAQ: MAZE) is a clinical-stage biopharmaceutical company, and its revenue generation over the next two to three years will primarily stem from its pipeline development and strategic collaborations rather than product sales. The company's future revenue growth is expected to be driven by the following factors:

  1. Advancement of Lead Clinical Programs: A significant driver will be the successful progression of its lead clinical candidates, MZE829 and MZE782, through clinical trials. Maze Therapeutics anticipates reporting topline proof-of-concept data for MZE829 in APOL1-mediated kidney disease (AMKD) by the end of the first quarter of 2026. For MZE782, following positive Phase 1 results, the company plans to initiate two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) in 2026. Positive data and advancement through these trials could trigger significant milestone payments from existing or new collaborators.
  2. New Licensing and Partnership Agreements: As a clinical-stage company, Maze Therapeutics generates revenue through strategic partnerships and licensing agreements. In 2024, the company recognized substantial license revenue from an upfront payment for MZE001, an investigational therapy for Pompe disease, which was exclusively licensed to Shionogi & Co., Ltd. Future revenue growth is expected from additional upfront payments, research funding, and milestone payments associated with similar new or existing collaborations for its other pipeline assets, leveraging its proprietary Maze Compass™ platform.
  3. Milestone Payments from Existing Collaborations: The license agreement for MZE001 with Shionogi & Co., Ltd. is likely structured with various development and regulatory milestone payments. While the initial upfront payment has been recognized, future payments contingent on the successful progression of MZE001 through clinical development and regulatory approvals would serve as a source of revenue growth within the forecast period.

AI Analysis | Feedback


Share Issuance

  • Maze Therapeutics priced its initial public offering (IPO) in January 2025, offering 8,750,000 shares of common stock at $16.00 per share, which aimed to raise approximately $140 million in gross proceeds.
  • The company granted underwriters a 30-day option to purchase up to an additional 1,312,500 shares of common stock at the IPO price.
  • In September 2025, Maze Therapeutics completed an oversubscribed private placement, raising approximately $150.0 million in gross proceeds through the issuance of 4,000,002 shares of common stock at $16.25 per share and 5,231,090 pre-funded warrants.

Inbound Investments

  • Maze Therapeutics completed a Series D financing round in December 2024, raising $115 million, co-led by Deep Track Capital and Frazier Life Sciences.
  • In January 2022, the company secured $190 million in Series C financing, led by Matrix Capital Management.
  • An oversubscribed private placement in September 2025 brought in approximately $150.0 million from new and existing investors, including Frazier Life Sciences and Deep Track Capital.

Outbound Investments

  • Maze Therapeutics entered into a Joint Venture with Broadwing Bio on December 7, 2020.

Capital Expenditures

  • Proceeds from the December 2024 Series D funding and the January 2025 IPO are intended to support the clinical development of lead candidates MZE829 and MZE782 for kidney disease programs.
  • Funds from the September 2025 private placement are allocated to advance MZE829 in APOL1-mediated kidney disease, initiate Phase 2 clinical trials for MZE782 in phenylketonuria and chronic kidney disease, and further develop its Compass platform.
  • The January 2022 Series C financing was aimed at advancing its MZE001 program into the clinic, expanding its precision medicine pipeline, and developing the Maze Compass drug discovery platform.

Latest Trefis Analyses

TitleDate
0DASHBOARDS 
1Maze Therapeutics Earnings Notes12/16/2025
2null10/17/2025
Title
0ARTICLES

Trade Ideas

Select ideas related to MAZE.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
VEEV_1302026_Monopoly_xInd_xCD_Getting_Cheaper01302026VEEVVeeva SystemsMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-14.6%-14.6%-15.7%
BIIB_1162026_Dip_Buyer_FCFYield01162026BIIBBiogenDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		19.5%19.5%0.0%
BMRN_1162026_Dip_Buyer_FCFYield01162026BMRNBioMarin PharmaceuticalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		9.7%9.7%0.0%
DOCS_1162026_Dip_Buyer_High_CFO_Margins_ExInd_DE01162026DOCSDoximityDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		-39.4%-39.4%-40.1%
CORT_1022026_Dip_Buyer_High_CFO_Margins_ExInd_DE01022026CORTCorcept TherapeuticsDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		4.6%4.6%-9.1%

Recent Active Movers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

MAZEVRTXAKTSALPSDCOYDFTXMedian
NameMaze The.Vertex P.Aktis On.ALPS Decoy Th.Definium. 
Mkt Price45.04469.2718.410.900.8017.2717.84
Mkt Cap2.1119.0----60.5
Rev LTM012,001--000
Op Inc LTM-1354,554---6-104-55
FCF LTM-1083,194---5-79-42
FCF 3Y Avg-1,832---12-65-12
CFO LTM-1073,631---5-79-42
CFO 3Y Avg-2,225---12-65-12

Growth & Margins

MAZEVRTXAKTSALPSDCOYDFTXMedian
NameMaze The.Vertex P.Aktis On.ALPS Decoy Th.Definium. 
Rev Chg LTM-100.0%8.9%-----45.5%
Rev Chg 3Y Avg-10.4%----10.4%
Rev Chg Q-100.0%9.5%-----45.2%
QoQ Delta Rev Chg LTM-100.0%2.4%-----48.8%
Op Mgn LTM-37.9%----37.9%
Op Mgn 3Y Avg-24.7%----24.7%
QoQ Delta Op Mgn LTM-38.7%----38.7%
CFO/Rev LTM-30.3%----30.3%
CFO/Rev 3Y Avg-20.5%----20.5%
FCF/Rev LTM-26.6%----26.6%
FCF/Rev 3Y Avg-17.0%----17.0%

Valuation

MAZEVRTXAKTSALPSDCOYDFTXMedian
NameMaze The.Vertex P.Aktis On.ALPS Decoy Th.Definium. 
Mkt Cap2.1119.0----60.5
P/S-9.9----9.9
P/EBIT-15.325.6----5.1
P/E-16.330.1----6.9
P/CFO-19.332.8----6.7
Total Yield-6.1%3.3%-----1.4%
Dividend Yield0.0%0.0%----0.0%
FCF Yield 3Y Avg-1.7%----1.7%
D/E0.00.0----0.0
Net D/E-0.2-0.0-----0.1

Returns

MAZEVRTXAKTSALPSDCOYDFTXMedian
NameMaze The.Vertex P.Aktis On.ALPS Decoy Th.Definium. 
1M Rtn1.6%6.2%-1.9%-10.9%-2.1%2.9%-0.2%
3M Rtn26.6%11.1%∞%-1.2%-2.6%14.8%11.1%
6M Rtn240.4%18.1%∞%-5.2%-2.6%14.8%14.8%
12M Rtn258.6%-0.5%131,400.0%-5.2%-2.6%14.8%7.1%
3Y Rtn182.4%59.8%373.9%-5.2%-2.6%14.8%37.3%
1M Excs Rtn0.6%5.2%-2.9%-11.8%-3.0%2.0%-1.1%
3M Excs Rtn31.5%5.3%∞%-2.3%-5.5%11.9%5.3%
6M Excs Rtn227.8%13.1%18,409,893.0%-12.2%-9.6%7.7%10.4%
12M Excs Rtn240.2%-10.4%306,721.4%-17.2%-14.6%2.8%-3.8%
3Y Excs Rtn116.5%-9.0%283.2%-71.1%-68.5%-51.1%-30.1%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20242023
Business of harnessing its understanding of human genetics and variant functionalization to develop00
Total00


Operating Income by Segment
$ Mil20242023
Business of harnessing its understanding of human genetics and variant functionalization to develop-99 
Total-99 


Assets by Segment
$ Mil20242023
Business of harnessing its understanding of human genetics and variant functionalization to develop 150
Total 150


Price Behavior

Price Behavior
Market Price$45.04 
Market Cap ($ Bil)2.1 
First Trading Date01/31/2025 
Distance from 52W High-6.9% 
   50 Days200 Days
DMA Price$19.63$12.88
DMA Trendupup
Distance from DMA129.5%249.8%
 3M1YR
Volatility57.3%98.7%
Downside Capture29.80111.19
Upside Capture154.29230.40
Correlation (SPY)10.4%18.9%
MAZE Betas & Captures as of 1/31/2026

 1M2M3M6M1Y3Y
Beta-2.47-0.510.571.37-0.21-0.18
Up Beta3.001.492.213.710.550.61
Down Beta-4.73-2.57-0.72-0.170.62-0.00
Up Capture-102%116%168%365%331%39%
Bmk +ve Days11223471142430
Stock +ve Days9203268131131
Down Capture-309%-50%-6%-33%102%66%
Bmk -ve Days9192754109321
Stock -ve Days11212957116116

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with MAZE
MAZE246.3%98.8%1.68-
Sector ETF (XLV)10.3%17.3%0.4121.0%
Equity (SPY)13.0%19.4%0.5118.9%
Gold (GLD)71.2%25.5%2.082.1%
Commodities (DBC)7.3%16.9%0.258.3%
Real Estate (VNQ)6.4%16.7%0.2016.8%
Bitcoin (BTCUSD)-30.2%44.9%-0.6612.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with MAZE
MAZE22.6%98.5%1.41-
Sector ETF (XLV)7.8%14.5%0.3619.8%
Equity (SPY)13.4%17.0%0.6217.9%
Gold (GLD)22.0%17.1%1.051.3%
Commodities (DBC)11.0%19.0%0.477.9%
Real Estate (VNQ)4.8%18.8%0.1615.9%
Bitcoin (BTCUSD)6.9%57.1%0.3412.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with MAZE
MAZE10.7%98.5%1.41-
Sector ETF (XLV)11.1%16.5%0.5619.8%
Equity (SPY)15.8%17.9%0.7617.9%
Gold (GLD)15.0%15.6%0.801.3%
Commodities (DBC)8.7%17.6%0.417.9%
Real Estate (VNQ)6.8%20.7%0.2915.9%
Bitcoin (BTCUSD)67.7%66.7%1.0712.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date1302026
Short Interest: Shares Quantity2.7 Mil
Short Interest: % Change Since 11520266.3%
Average Daily Volume0.5 Mil
Days-to-Cover Short Interest5.9 days
Basic Shares Quantity45.8 Mil
Short % of Basic Shares6.0%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/6/2025-3.5%7.5%37.6%
8/12/2025-1.0%-2.1%80.5%
3/31/2025-3.6%-20.6%-23.0%
SUMMARY STATS   
# Positive012
# Negative321
Median Positive 7.5%59.0%
Median Negative-3.5%-11.3%-23.0%
Max Positive 7.5%80.5%
Max Negative-3.6%-20.6%-23.0%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202511/06/202510-Q
06/30/202508/12/202510-Q
03/31/202505/14/202510-Q
12/31/202403/31/202510-K
09/30/202401/31/2025424B4
06/30/202409/13/2024DRS/A

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Bernstein, HaroldPresident, R&D & CMODirectSell106202640.434,432  Form
2Bernstein, HaroldPresident, R&D & CMODirectSell106202640.00412  Form
3Bachrodt, AmySVP, FinanceDirectSell106202639.155,000195,754507,589Form
4Dandekar, AtulCSBODirectSell1231202540.5672,4002,936,763426,034Form
5Dandekar, AtulCSBODirectSell1231202540.361004,036423,901Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.